The RESTORE trial: what did we learn about multiple sclerosis?
Steven
S
Karceski
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000628:therapy*; D000069442:Natalizumab; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D014481:United States
D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab